CC
Therapeutic Areas
BioAtla Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Mecbotamab vedotin (BA3011) | Advanced Solid Tumors (e.g., Sarcoma, NSCLC) | Phase 2 |
| Ozuriftamab vedotin (BA3021) | Advanced Solid Tumors (e.g., NSCLC, Melanoma) | Phase 2 |
| CAB-CTLA-4 (BA3071) | Advanced Solid Tumors | Phase 1/2 |
| CAB-CD19 x CD3 T-cell Engager | B-cell Malignancies | Preclinical |
Leadership Team at BioAtla
JS
Jay Short, Ph.D.
Chairman, Chief Executive Officer & Cofounder
RW
Richard Waldron
Chief Financial Officer
ES
Eric Sievers, M.D.
Chief Medical Officer
SL
Sheri Lydick
Chief Commercial Officer
WB
William Boyle, Ph.D.
Senior Research Fellow
JB
James Butler, J.D., Ph.D.
Intellectual Property Counsel
GF
Gerhard Frey, Ph.D.
Senior Vice President, Technology Development
MM
Michael Melnick, Ph.D.
Vice President of CMC
SM
Susie Melody
Senior Vice President of Human Resources
MS
Monica Sullivan
Senior Vice President of Intellectual Property & Contracts